Journal of Antimicrobial Chemotherapy (2006) 58, 458–461 doi:10.1093/jac/dkl237 Advance Access publication 6 June 2006



Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes

Brunella Posteraro¹, Maurizio Sanguinetti¹*, Barbara Fiori¹, Marilena La Sorda¹, Teresa Spanu¹, Dominique Sanglard² and Giovanni Fadda¹

¹Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy; ²Institut de Microbiologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

Received 16 March 2006; returned 14 April 2006; revised 10 May 2006; accepted 12 May 2006

Objectives: Several studies have documented the potent *in vitro* activity of caspofungin against *Candida* spp. This is of special concern for *Candida glabrata* infections that are often resistant to many azole antifungal agents and, consequently, difficult to treat. The aim of the present study was to expand the data on the *in vitro* activity of caspofungin against azole-resistant isolates of *C. glabrata*.

Methods: A total of 50 clinical isolates of *C. glabrata* were tested for susceptibility to caspofungin. The isolates were cross-resistant to multiple azoles, including fluconazole, itraconazole, ketoconazole and voriconazole. Expression of the resistance-related *CgCDR1* and *CgCDR2* genes was evaluated by quantitative RT–PCR analysis. The MICs of caspofungin were determined by using the National Committee for Clinical Laboratory Standards M27-A2 reference method.

Results: C. glabrata isolates exhibited increased expression of the CDR efflux pump(s), and this was in accordance with their high-level azole resistance. In contrast, all the isolates were highly susceptible to caspofungin (100% of isolates were inhibited at ≤ 1 mg/L).

Conclusions: Our results represent further evidence for the excellent antifungal potency of caspofungin, particularly against *C. glabrata* isolates expressing cross-resistance to azoles.

Keywords: antifungals, susceptibility testing, CgCDR genes

Introduction

Candida glabrata infections have markedly increased in the past decades and, when invasive, are associated with a high mortality rate, especially in immunocompromised patients such as intensive-care, post-surgical and neutropenic patients.¹ This, in part, has been attributed to the reduced susceptibility of this pathogen to antifungal agents, especially the azoles.² Recent studies revealed that the MICs of extended-spectrum triazoles (fluconazole, itraconazole and voriconazole) for C. glabrata were higher than those seen for most Candida albicans isolates.3-6 Fluconazole-resistant isolates have been found not only in AIDS patients with oropharyngeal candidiasis, but also in fungaemic patients and among vaginal isolates as a consequence of widespread and often indiscriminate use of the drug.⁷ C. glabrata is able to rapidly develop azole resistance, which is probably related to the haploid state of the microorganism.² In this context, studying the resistance mechanisms of this pathogenic yeast may provide answers in developing new antifungal agents.^{6,8}

Caspofungin is an echinocandin with potent fungicidal activity against many *Candida* species^{3,9} and could be particularly useful to treat *C. glabrata* infections, which often develop resistance to azoles. To further demonstrate the *in vitro* efficacy of this promising new antifungal agent in *C. glabrata*, we report here caspofungin susceptibility of a large collection of clinical isolates which were cross-resistant to multiple azoles. Molecular studies showed that azole resistance in these isolates is associated with the up-regulation of the ABC transporter genes *CgCDR1* and *CgCDR2*.

Materials and methods

Yeast isolates and antifungal susceptibility testing

A total of 50 clinical isolates of azole-resistant *C. glabrata* were tested: 30 isolates were recovered from blood (4 isolates), respiratory tract (10), vagina (3), mouth (1), urine (10), skin (1) and drainage fluid (1) of patients hospitalized between January 2004 and June

*Corresponding author. Tel: +39-06-30154964; Fax: +39-06-3051152; E-mail: msanguinetti@rm.unicatt.it

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Table 1. In vitro activity of caspofungin and azole antifungal agents against 80 clinical isolates of C. glabrata stratified by fluconazole susceptibility

Fluconazole susceptibility category ^a	No. tested	Antifungal agent	MIC range (mg/L)	MIC ₅₀ (mg/L)	MIC ₉₀ (mg/L)
S	15	caspofungin	0.03-0.125	0.06	0.125
		itraconazole	0.125-0.5	0.25	0.5
		ketoconazole	0.06-0.25	0.125	0.25
		voriconazole	0.06-0.25	0.125	0.125
S-DD	15	caspofungin	0.03-0.25	0.125	0.25
		itraconazole	0.125-2	0.5	1
		ketoconazole	0.06-0.5	0.125	0.5
		voriconazole	0.125-1	0.25	0.5
R	50	caspofungin	0.06-1	0.25	1
		itraconazole	2->8	8	>8
		ketoconazole	1-8	4	4
		voriconazole	2-8	4	8

^aS, MIC \leq 8 mg/L; S-DD, MIC = 16–32 mg/L; R, MIC \geq 64 mg/L.

2005, and 20 other isolates, cultured from various patient specimens (6 blood, 5 urine, 3 vagina, 2 respiratory tract, 2 mouth, 1 skin and 1 drainage fluid) before 2004, had been explored for molecular mechanisms of antifungal resistance in a previous study.⁶ Each isolate represented an individual infectious episode. The isolates showed high MICs of multiple azoles, as determined by the broth microdilution method (Table 1). A panel of 30 fluconazole-susceptible or fluconazole-susceptible dose-dependent (S-DD) isolates was also included. All isolates were identified to the species level by standard $methods^{10}$ and stored as 20% glycerol stocks until use. Prior to testing, each isolate was subcultured onto Sabouraud dextrose agar. C. glabrata ATCC 36909 reference strain and two well-characterized *C. glabrata* isolates, DSY562 (a susceptible isolate) and DSY565 (a resistant isolate),¹¹ were included as controls. Antifungal susceptibility testing was performed by the broth microdilution method in RPMI with 2% glucose according to the M27-A2 document of the Clinical and Laboratory Standards Institute (CLSI, formerly the NCCLS).¹² The inoculum suspensions were adjusted spectrophotometrically at 530 nm to match the concentration of $1.5 \pm 1.0 \times 10^3$ cells/mL. Stock solutions of caspofungin (Merck & Co., Whitehouse Station, PA, USA), fluconazole (Pfizer, Inc., New York, NJ, USA), itraconazole (Janssen, Beerse, Belgium), ketoconazole (Sigma Aldrich, Milan, Italy) and voriconazole (Pfizer) were prepared in water (caspofungin and fluconazole) or dimethyl sulphoxide (itraconazole, ketoconazole and voriconazole). The final concentrations of the antifungal agents were 0.008-8 mg/L for caspofungin, itraconazole, ketoconazole and voriconazole and 0.125-128 mg/L for fluconazole. The trays were incubated at 35°C, and MIC end points were read at 48 h. All tests were carried out in duplicate. For caspofungin, the MIC end point was defined as the lowest concentration determining complete inhibition of growth. This end point was chosen based on the fungicidal activity of caspofungin as already described.⁹ For azoles, the MIC end point was defined as the lowest concentration that produced a prominent decrease in turbidity (80% inhibition) compared with that of the growth control. The interpretive criteria used for fluconazole, itraconazole and voriconazole were those published by the CLSI.^{12,13} Interpretive breakpoints have not yet been established for either ketoconazole or voriconazole, but we used susceptibility breakpoints

of ≤ 0.125 and ≤ 1 mg/L, respectively.⁶ The CLSI quality control strains *Candida krusei* ATCC 6258 and *Candida parapsilosis* ATCC 22019 were tested and MICs were within the expected range.

Rhodamine 6G accumulation assay

The rhodamine 6G accumulation assay was performed as described previously.^{11,14} Following growth overnight in YEPD (1% yeast extract, 2% peptone, 2% glucose) liquid medium at 30°C, yeast cells were diluted 100-fold in 5 mL of the same medium. The culture was grown to reach a cell density of $\sim 10^7$ cells/mL, then placed at 4°C and divided into 1 mL aliquots. Labelling of the cells (10⁷) with 10 μ M rhodamine 6G (Società Italiana Chimici, Rome, Italy) was performed under constant shaking for 30 min at 30°C, then stopped by placing reaction tubes on ice. The labelled cells were diluted 40-fold in ice-cold 0.1 M phosphate-buffered saline (PBS) at pH 7.0 and then subjected to flow cytometry using a Coulter EPICS XL instrument (Beckman Coulter, Brea, CA, USA). Experiments were repeated two times.

Expression levels of ABC transporter genes

Quantitative expression of the *CgCDR1* and *CgCDR2* genes was performed by real-time RT–PCR analysis with an i-Cycler iQ system (Bio-Rad Laboratories, Hercules, CA, USA), following a previously described protocol.⁶ Relative quantification of the target gene was carried out by using a primer pair and a Taqman probe in combination with primers and a probe specific for the *URA3* reference gene. Each reaction was performed in triplicate. For each isolate, fold increases in gene expression were calculated from the mean normalized expression relative to the mean normalized expression of the DSY562 isolate, used as a susceptible control.¹⁵ Genes with a $\Delta C_{\rm T}$ value, calculated as $C_{\rm T}$ [test gene]– $C_{\rm T}$ [*URA3*], that fell over the 3-SD range measured in the azole-susceptible isolates were considered overexpressed, as reported previously.¹⁶

Results and discussion

Table 1 summarizes the in vitro susceptibility of 80 C. glabrata clinical isolates to caspofungin, itraconazole, ketoconazole and voriconazole stratified by fluconazole susceptibility category. With respect to fluconazole MIC, the isolates fell into the following groups: susceptible (15 isolates), S-DD (15 isolates) and resistant (50 isolates). All fluconazole-resistant isolates were also cross-resistant to the other azoles tested (Table 1), and this phenotype was found to be associated with the overexpression of drug efflux pump-encoding CgCDR genes. The expression of CgCDR1 and CgCDR2 was strongly increased in the majority of the 50 azole-resistant isolates compared with that of the susceptible control isolate DSY562, but not in the 15 azole-susceptible isolates studied (Figure 1). Of the resistant isolates 46 exhibited 12.4- to 483.0-fold up-regulation of the ABC transporter gene CgCDR1. Notably, 27 of these 46 also exhibited 3.9- to 70.6-fold up-regulation of CgCDR2, with the remaining 4 isolates showing 26.1- to 61.2-fold up-regulation of this second ABC transporter gene. The 15 fluconazole-S-DD isolates up-regulated CgCDR1 or CgCDR2 (Figure 1), but the levels of up-regulation were significantly less than those by the resistant isolates studied (109.9- to 5.5-fold for CgCDR1 and 17.4- to 2.6-fold for CgCDR2). Furthermore, the increased expression of efflux pumps in the fluconazole-resistant and fluconazole-S-DD isolates was also accompanied by decreased accumulation of rhodamine 6G, as shown by their mean fluorescence values, which differed from



Figure 1. Expression of ABC transporters CgCDR1 (a) and CgCDR2 (b) and rhodamine 6G accumulation (c) in *C. glabrata* clinical isolates. With respect to fluconazole, isolates were defined as resistant (R), susceptible-dose dependent (S-DD) or susceptible (S). Fold increases in gene expression were determined by RT–PCR analysis relative to DSY562. Fluorescence values were determined by flow cytometry. The mean value (a and b) or the geometric mean value (c) for each group is indicated by a dark solid horizontal line.

those of the susceptible isolates by 96.1- and 37.0-fold, respectively (Figure 1). In contrast, caspofungin was very active *in vitro* against all the fluconazole-resistant and fluconazole-S-DD isolates and, as expected, against the fluconazole-susceptible isolates. MIC₉₀ (MIC at which 90% of the isolates were inhibited) of fluconazole-resistant isolates was 1 mg/L. MIC₉₀s of fluconazole-S-DD isolates and fluconazole-susceptible isolates were 0.25 and 0.125 mg/L, respectively. For all the isolates, the MIC of caspofungin was ≤ 1 mg/L. Low MICs (0.06 mg/L) of caspofungin were also obtained for the *C. glabrata* reference strain, ATCC 36909, and two well-characterized *C. glabrata* isolates, DSY562 and DSY565.

Cross-resistance within a class of antimicrobial agents is an important issue, especially if therapeutic options are limited by a poor number of available compounds as for the antifungal agents. Although the new systemic antifungal triazoles (ravuconazole and voriconazole) are more active *in vitro* than fluconazole and itraconazole against *Candida* spp.,¹⁷ cross-resistance between fluconazole and ravuconazole has been observed, so that fluconazole was recently proposed as a surrogate marker to predict the susceptibility of *Candida* spp. to ravuconazole.¹⁸ The crossresistance involving ravuconazole,¹⁸ like that involving voriconazole,^{4,6} applies most directly to fluconazole-resistant *C. glabrata*. As stated by Sobel,⁷ *C. glabrata* can be considered the Achilles heel of all available azoles, thus *C. glabrata*.

Our results showed that caspofungin had excellent activity against fluconazole (multiazole)-resistant isolates, as well as against isolates susceptible and dose-dependent susceptible to fluconazole. This is not surprising considering that the echinocandin caspofungin belongs to a class of antifungal agents that act by inhibiting the cell wall glucan synthesis. Interestingly, fluconazole-resistant isolates showed a higher MIC₉₀ value compared with fluconazole-S-DD or fluconazole-susceptible isolates. This difference indicates that azole resistance can contribute to an increase in caspofungin MIC. The basis for such a difference is still unknown.

In conclusion, the present study confirms the efficacy of caspofungin against clinical isolates of *C. glabrata*, but, for the first time, the potent activity of this drug was assessed with a large number of *C. glabrata* isolates whose cross-azole resistance was well documented by molecular methods. Furthermore, these findings support the use of caspofungin to treat those *C. glabrata* infections for which amphotericin B represents the sole therapeutic choice.

Acknowledgements

This work was supported by grants from the Istituto Superiore di Sanità (National Program of Research on AIDS, No. 50 F.31) and from the Università Cattolica del S. Cuore (Fondi Ateneo Linea D1-2005).

Transparency declarations

None to declare.

References

1. Marr KA. Invasive *Candida* infections: the changing epidemiology. *Oncology* 2004; 18: 9–14.

Caspofungin against azole-resistant Candida glabrata

2. Fidel PL, Vazquez JA, Sobel JD. *Candida glabrata*: review of epidemiology, pathogenesis, and clinical disease with comparison to *C. albicans. Clin Microbiol Rev* 1999; **12**: 80–96.

3. Pfaller MA, Diekema DJ, Messer SA *et al. In vitro* activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of *Candida* spp., including 157 fluconazole-resistant isolates. *Antimicrob Agents Chemother* 2003; **47**: 1068–71.

4. Pfaller MA, Messer SA, Boyken L *et al.* Geographic variation in the susceptibilities of invasive isolates of *Candida glabrata* to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. *J Clin Microbiol* 2004; **42**: 3142–6.

5. Hajjeh RA, Sofair AN, Harrison LH *et al.* Incidence of bloodstream infections due to *Candida* species and *in vitro* susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. *J Clin Microbiol* 2004; **42**: 1519–27.

6. Sanguinetti M, Posteraro B, Fiori B *et al.* Mechanisms of azole resistance in clinical isolates of *Candida glabrata* collected during a hospital survey of antifungal resistance. *Antimicrob Agents Chemother* 2005; **49**: 668–79.

7. Sobel JD. Management of infections caused by *Candida glabrata*. *Curr Infect Dis Rep* 2000; **2**: 424–8.

8. Borst A, Raimer MT, Warnock DW *et al.* Rapid acquisition of stable azole resistance by *Candida glabrata* isolates obtained before the clinical introduction of fluconazole. *Antimicrob Agents Chemother* 2005; **49**: 783–7.

9. Pfaller MA, Messer SA, Boyken L *et al.* Caspofungin activity against clinical isolates of fluconazole-resistant *Candida. J Clin Microbiol* 2003; **41**: 5729–31.

10. Warren NG, Hazen KC. *Candida, Cryptococcus,* and other yeasts of medical importance. In: Murray PR, Baron EJ, Pfaller MA,

Tenover FC, Yolken RH, eds. *Manual of Clinical Microbiology*, 7th edn. Washington, DC, USA: ASM Press; 1184–99.

11. Sanglard D, Ischer F, Calabrese D *et al.* The ATP binding cassette transporter gene *CgCDR1* from *Candida glabrata* is involved in the resistance of clinical isolates to azole antifungal agents. *Antimicrob Agents Chemother* 1999; **43**: 2753–65.

12. National Committee for Clinical Laboratory Standards. *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A2.* NCCLS, Wayne, PA, USA, 2002.

13. Pfaller MA, Diekema DJ, Rex JH *et al.* Correlation of MIC with outcome for *Candida* species tested against voriconazole: analysis and proposal for interpretive breakpoints. *J Clin Microbiol* 2006; **44**: 819–26.

14. Posteraro B, Sanguinetti M, Sanglard D *et al.* Identification and characterization of a *Cryptococcus neoformans* ATP binding cassette (ABC) transporter-encoding gene, *CnAFR1*, involved in the resistance to fluconazole. *Mol Microbiol* 2003; **47**: 357–71.

15. Peirson SN, Butler JN, Foster RG. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. *Nucleic Acids Res* 2003; **31**: e73.

16. Chau AS, Mendrick CA, Sabatelli FJ *et al.* Application of realtime quantitative PCR to molecular analysis of *Candida albicans* strains exhibiting reduced susceptibility to azoles. *Antimicrob Agents Chemother* 2004; **48**: 2124–31.

17. Pfaller MA, Messer SA, Hollis RJ *et al. In vitro* activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of *Candida* spp. *Antimicrob Agents Chemother* 2002; **46**: 1723–7.

18. Pfaller MA, Messer SA, Boyken L *et al.* Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of *Candida* spp. *J Clin Microbiol* 2004; **42**: 3137–41.